Display options
Cite
Zemanova M, Cernovska M, Havel L, et al. Autologous dendritic cell-based immunotherapy (DCVAC/LuCa) and carboplatin/paclitaxel in advanced non-small cell lung cancer: A randomized, open-label, phase I/II trial. Cancer Treat Res Commun. 2021;28:100427doi: 10.1016/j.ctarc.2021.100427.
Zemanova, M., Cernovska, M., Havel, L., Bartek, T., Lukesova, S., Jakesova, J., Vanasek, J., Reiterer, P., Kultan, J., Andrasina, I., Siskova, L., Koubkova, L., Skrickova, J., Salajka, F., Pesek, M., Klepetko, P., Beniak, J., Fricke, H., Kadlecova, P., Korolkiewicz, R. P., Hraska, M., Bartunkova, J., & Spisek, R. (2021). Autologous dendritic cell-based immunotherapy (DCVAC/LuCa) and carboplatin/paclitaxel in advanced non-small cell lung cancer: A randomized, open-label, phase I/II trial. Cancer treatment and research communications, 28100427. https://doi.org/10.1016/j.ctarc.2021.100427
Zemanova, Milada, et al. "Autologous dendritic cell-based immunotherapy (DCVAC/LuCa) and carboplatin/paclitaxel in advanced non-small cell lung cancer: A randomized, open-label, phase I/II trial." Cancer treatment and research communications vol. 28 (2021): 100427. doi: https://doi.org/10.1016/j.ctarc.2021.100427
Zemanova M, Cernovska M, Havel L, Bartek T, Lukesova S, Jakesova J, Vanasek J, Reiterer P, Kultan J, Andrasina I, Siskova L, Koubkova L, Skrickova J, Salajka F, Pesek M, Klepetko P, Beniak J, Fricke H, Kadlecova P, Korolkiewicz RP, Hraska M, Bartunkova J, Spisek R. Autologous dendritic cell-based immunotherapy (DCVAC/LuCa) and carboplatin/paclitaxel in advanced non-small cell lung cancer: A randomized, open-label, phase I/II trial. Cancer Treat Res Commun. 2021;28:100427. doi: 10.1016/j.ctarc.2021.100427. Epub 2021 Jun 26. PMID: 34284344.
Copy Download .nbib Format: NLM
Share it on

Cancer Treat Res Commun. 2021;28:100427. doi: 10.1016/j.ctarc.2021.100427. Epub 2021 Jun 26.

Autologous dendritic cell-based immunotherapy (DCVAC/LuCa) and carboplatin/paclitaxel in advanced non-small cell lung cancer: A randomized, open-label, phase I/II trial.

Cancer treatment and research communications

Milada Zemanova, Marketa Cernovska, Libor Havel, Tomas Bartek, Sarka Lukesova, Jitka Jakesova, Jaroslav Vanasek, Pavel Reiterer, Juraj Kultan, Igor Andrasina, Lenka Siskova, Leona Koubkova, Jana Skrickova, Frantisek Salajka, Milos Pesek, Petr Klepetko, Juraj Beniak, Harald Fricke, Pavla Kadlecova, Roman P Korolkiewicz, Marek Hraska, Jirina Bartunkova, Radek Spisek

Affiliations

  1. Department of Oncology, General Teaching Hospital, Prague, Czech Republic; First Faculty of Medicine, Charles University, Prague, Czech Republic.
  2. First Faculty of Medicine, Charles University, Prague, Czech Republic; Department of Respiratory Medicine, Thomayer Hospital, Prague, Czech Republic.
  3. Department of Respiratory Medicine and Tuberculosis, University Hospital Ostrava, Ostrava, Czech Republic.
  4. Department of Oncology, Hospital Nachod, Nachod, Czech Republic.
  5. Department of Oncology, Hospital Pribram, Pribram, Czech Republic.
  6. Oncology Centre Multiscan, Pardubice, Czech Republic.
  7. Department of Pneumology, Masaryk Hospital Usti and Labem, Usti and Labem, Czech Republic.
  8. Department of Respiratory Medicine, University Hospital Olomouc, Olomouc, Czech Republic.
  9. Department of Oncology, Vychodoslovensky onkologicky ustav, a.s., Kosice, Slovak Republic.
  10. Department of Oncology, Hospital of Tomas Bata in Zlin, Zlin, Czech Republic.
  11. Department of Pneumology, 2nd Faculty of Medicine, University Hospital Motol, Charles University, Prague, Prague, Czech Republic.
  12. Department of Respiratory Medicine and Tuberculosis, University Hospital Brno, Brno, Czech Republic.
  13. Department of Pneumology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic.
  14. Department of Pneumology, University Hospital Pilsen, Charles University in Prague, Prague, Czech Republic.
  15. Avicennus Oncology, Kutna Hora, Czech Republic.
  16. POKO Poprad, Poprad, Slovak Republic.
  17. SOTIO a.s., Prague, Czech Republic.
  18. SOTIO a.s., Prague, Czech Republic. Electronic address: [email protected].

PMID: 34284344 DOI: 10.1016/j.ctarc.2021.100427

Abstract

PURPOSE: To investigate the efficacy and safety of an active cellular immunotherapy (DCVAC/LuCa) and chemotherapy in patients with stage IV non-small cell lung cancer (NSCLC).

PATIENTS AND METHODS: SLU01 was a multicenter, open-label, parallel-group, randomized, phase I/II trial. NSCLC patients were randomized in a ratio of 1:1:1 to receive: DCVAC/LuCa and chemotherapy (carboplatin and paclitaxel; Group A); DCVAC/LuCa, chemotherapy, pegylated interferon-α2b, and hydroxychloroquine (Group B); or chemotherapy alone (Group C). DCVAC/LuCa was administered subcutaneously every 3-6 weeks (up to 15 doses). The primary endpoint was overall survival (OS). During the study, enrollment into Group B was discontinued for strategic reasons.

RESULTS: Forty-five patients were randomized to Group A, 29 patients to Group B, and 38 patients to Group C. The median OS in the modified intention-to-treat (mITT) population was 3.7 months longer in Group A than in Group C (15.5 vs. 11.8 months; p = 0.0179; hazard ratio = 0.54; 95% confidence interval: 0.32-0.91). This OS effect was consistent across subgroups of the mITT population (females, males, current smokers, former smokers, and patients with non-squamous and squamous cell histology). The most common treatment-emergent adverse events of any grade reported in Groups A, B, and C, respectively, were neutropenia (50.0%, 29.6%, and 20.6%), fatigue (40.0%, 18.5%, and 20.6%), anemia (35.0%, 44.4%, and 32.4%), paresthesia (27.5%, 25.9%, and 17.6%), and alopecia (25.0%, 29.6%, and 41.2%).

CONCLUSION: DCVAC/LuCa in combination with carboplatin and paclitaxel extended OS and was well tolerated.

Copyright © 2021. Published by Elsevier Ltd.

Keywords: Cellular immunotherapy; Dendritic cells and a platinum doublet; Immuno-oncology; Immunotherapy combined with platinum-based chemotherapy; Metastatic non-small cell lung cancer

Publication Types